002317 众生药业
交易中 09-04 10:21:15
资讯
新帖
简况
众生药业：乐睿灵已纳入2025年版国家医保目录
证券之星 · 09-03 20:48
众生药业：乐睿灵已纳入2025年版国家医保目录
众生药业：来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物
证券之星 · 09-03 20:48
众生药业：来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物
股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》
证券之星 · 09-03 01:17
股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》
众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理
智通财经 · 09-02 17:59
众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理
众生药业（002317）披露控股子公司获得来瑞特韦片晶型发明专利证书，8月27日股价上涨6.01%
证券之星 · 08-27
众生药业（002317）披露控股子公司获得来瑞特韦片晶型发明专利证书，8月27日股价上涨6.01%
8月27日众生药业涨6.01%，兴全趋势LOF基金重仓该股
证券之星 · 08-27
8月27日众生药业涨6.01%，兴全趋势LOF基金重仓该股
开源证券：给予众生药业买入评级
证券之星 · 08-27
开源证券：给予众生药业买入评级
众生药业（002317）2026年中报简析：净利润同比下降40.7%
证券之星 · 08-26
众生药业（002317）2026年中报简析：净利润同比下降40.7%
众生药业（002317）披露2026年半年度报告，8月24日股价下跌3.17%
证券之星 · 08-24
众生药业（002317）披露2026年半年度报告，8月24日股价下跌3.17%
众生药业（002317）披露收购控股子公司部分股权暨关联交易公告，8月17日股价上涨2.88%
证券之星 · 08-17
众生药业（002317）披露收购控股子公司部分股权暨关联交易公告，8月17日股价上涨2.88%
众生药业最新公告：拟2826万美元收购控股子公司众生睿创12.06%股权
证券之星 · 08-17
众生药业最新公告：拟2826万美元收购控股子公司众生睿创12.06%股权
公司问答丨众生药业：RAY1225注射液已获得FDA批准在美国开展超重或肥胖患者的II期临床研究
格隆汇 · 08-17
公司问答丨众生药业：RAY1225注射液已获得FDA批准在美国开展超重或肥胖患者的II期临床研究
众生药业：RAY1225注射液获FDA批准在美国开展II期临床研究
证券之星 · 08-17
众生药业：RAY1225注射液获FDA批准在美国开展II期临床研究
众生药业：RAY1225注射液III期临床试验已完成全部参与者入组
证券之星 · 08-12
众生药业：RAY1225注射液III期临床试验已完成全部参与者入组
众生药业：乐睿灵®已形成医疗机构终端+线上平台的核心销售渠道体系
证券之星 · 08-12
众生药业：乐睿灵®已形成医疗机构终端+线上平台的核心销售渠道体系
众生药业：中国民营药企穿越周期最朴素的样子
蓝鲸财经 · 08-11
众生药业：中国民营药企穿越周期最朴素的样子
股市必读：众生药业新发布《关于全资子公司获得布瑞哌唑化学原料药上市申请批准通知书的公告》
证券之星 · 08-03
股市必读：众生药业新发布《关于全资子公司获得布瑞哌唑化学原料药上市申请批准通知书的公告》
众生药业(002317.SZ)：原料药布瑞哌唑获得化学原料药上市申请批准
智通财经 · 07-31
众生药业(002317.SZ)：原料药布瑞哌唑获得化学原料药上市申请批准
公司问答丨众生药业：已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请 目前正在审评审批进程中
格隆汇 · 07-30
公司问答丨众生药业：已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请 目前正在审评审批进程中
众生药业（002317）披露使用闲置自有资金进行委托理财的进展公告，7月28日股价下跌5.26%
证券之星 · 07-28
众生药业（002317）披露使用闲置自有资金进行委托理财的进展公告，7月28日股价下跌5.26%
加载更多
公司概况
公司名称：
广东众生药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-12-11
主营业务：
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是中成药、化学药、原料药及中间体、中药材及中药饮片。
发行价格：
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":24.97,"timestamp":1788488475000,"preClose":24.89,"halted":0,"volume":3925400,"delay":0,"changeRate":0.0032,"floatShares":768000000,"shares":850000000,"eps":0.2345,"marketStatus":"交易中","change":0.08,"latestTime":"09-04 10:21:15","open":25.04,"high":25.13,"low":24.79,"amount":98163400,"amplitude":0.0137,"askPrice":25,"askSize":6,"bidPrice":24.97,"bidSize":6,"shortable":0,"etf":0,"ttmEps":0.2345,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1788492600000},"marketStatusCode":2,"adr":0,"adjPreClose":24.89,"symbolType":"stock","openAndCloseTimeList":[[1788485400000,1788492600000],[1788498000000,1788505200000]],"highLimit":27.38,"lowLimit":22.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":5.28,"roa":"--","peRate":106.481876,"roe":"2.73%","epsLYR":0.33,"committee":-0.140893,"marketValue":21223000000,"turnoverRate":0.0051,"status":0,"floatMarketCap":19178000000},"requestUrl":"/m/hq/s/002317","defaultTab":"news","newsList":[{"id":"2664346872","title":"众生药业：乐睿灵已纳入2025年版国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2664346872","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664346872?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:48","pubTimestamp":1788439702,"startTime":"0","endTime":"0","summary":"公司新冠创新药来瑞特韦片已纳入2025年版国家医保目录，公司打造高效的营销队伍，搭建五大核心标杆区域市场，以学术驱动、渠道协同、终端渗透为核心，全面加速创新药商业化进程。另外，公司乐睿灵已获得常规批准，目前正稳步推进乐睿灵向基层医疗机构、零售药店的拓展落地，逐步完善从等级医院到基层医疗机构、零售药店的全域渠道布局，全方位提升药品可及性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300039697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872366","title":"众生药业：来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872366","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664872366?lang=zh_cn&edition=full","pubTime":"2026-09-03 20:48","pubTimestamp":1788439701,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业09月02日在投资者关系平台上答复投资者关心的问题。7-8月新冠流行回升，线上平台乐睿灵销量大幅增长，公司目前该产品实际出货情况如何？来瑞特韦片是全球首个获得常规批准的3CL单药抗新冠病毒感染口服药物，能够快速降低病毒滴度、缩短病毒转阴时间、显著缓解临床症状。公司将密切关注疾病动态情况，积极做好药品生产和销售工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300039696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664843263","title":"股市必读：众生药业新发布《关于控股子公司收到一类创新药昂拉地韦片新增适应症临床试验注册申请获得受理的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664843263","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664843263?lang=zh_cn&edition=full","pubTime":"2026-09-03 01:17","pubTimestamp":1788369431,"startTime":"0","endTime":"0","summary":"公司公告汇总：子公司众生睿创于9月1日使用闲置自有资金7000万元购买结构性存款产品，期限56天，均为保本浮动收益型。产品均为保本浮动收益型，资金来源为闲置自有资金，投资期限内任一时点余额未超过董事会审批额度。公司已制定相关管理制度并采取多项风险控制措施，确保资金安全。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002317","BK0077","BK1574","BK0188","BK0239","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818429","title":"众生药业(002317.SZ)：昂拉地韦片新增适应症临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818429","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664818429?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:59","pubTimestamp":1788343190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新药物昂拉地韦片新增适应症“治疗高并发症风险甲型流感”的药物临床试验申请获得国家药品监督管理局(NMPA)受理，并收到《受理通知书》。据悉，昂拉地韦片是具有明确作用机制和全球自主知识产权的全球首款流感RNA聚合酶PB2蛋白抑制剂，已于2025年5月获NMPA批准上市。此次昂拉地韦片新增适应症拟开展III期临床研究入组12岁及以上青少年和成人甲型流感参与者，评估昂拉地韦片治疗甲型流感病毒感染且存在流感相关并发症高风险参与者的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","002317","MDTX","BK0188","BK0239","BK0077","PSYK","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662847708","title":"众生药业（002317）披露控股子公司获得来瑞特韦片晶型发明专利证书，8月27日股价上涨6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662847708","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662847708?lang=zh_cn&edition=full","pubTime":"2026-08-27 17:51","pubTimestamp":1787824271,"startTime":"0","endTime":"0","summary":"截至2026年8月27日收盘，众生药业报收于26.1元，较前一交易日上涨6.01%，最新总市值为221.83亿元。公司于近日披露《关于控股子公司获得发明专利证书的公告》。该专利为公司口服抗新型冠状病毒感染新药来瑞特韦片的晶型专利，属于项目核心专利。乐睿灵是公司自主研发的全球首个获得常规批准的3CL单药抗新冠病毒一类创新药，具有安全性更优、适用人群更广的特点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700042067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0077","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774092","title":"8月27日众生药业涨6.01%，兴全趋势LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774092","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662774092?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:49","pubTimestamp":1787820594,"startTime":"0","endTime":"0","summary":"证券之星消息，8月27日众生药业涨6.01%，收盘报26.1元，换手率3.77%，成交量28.96万手，成交额7.35亿元。重仓众生药业的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为兴证全球基金的兴全趋势LOF。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700039281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","163402","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775976","title":"开源证券：给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662775976?lang=zh_cn&edition=full","pubTime":"2026-08-27 14:40","pubTimestamp":1787812845,"startTime":"0","endTime":"0","summary":"开源证券股份有限公司余汝意,巢舒然近期对众生药业进行研究并发布了研究报告《公司信息更新报告：创新管线稳步推进，ZSP1601临床IIb期数据超预期》，给予众生药业买入评级。最新盈利预测明细如下：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家。本文数据来源于开源证券股份有限公司，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700031177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662750572","title":"众生药业（002317）2026年中报简析：净利润同比下降40.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662750572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662750572?lang=zh_cn&edition=full","pubTime":"2026-08-26 06:23","pubTimestamp":1787696600,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期众生药业发布2026年中报。根据财报显示，众生药业净利润同比下降40.7%。截至本报告期末，公司营业总收入10.0亿元，同比下降23.03%，归母净利润1.11亿元，同比下降40.7%。按单季度数据看，第二季度营业总收入3.76亿元，同比下降43.47%，第二季度归母净利润1160.1万元，同比下降88.98%。本文数据来源于众生药业2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600009914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661274904","title":"众生药业（002317）披露2026年半年度报告，8月24日股价下跌3.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661274904","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661274904?lang=zh_cn&edition=full","pubTime":"2026-08-24 22:03","pubTimestamp":1787580196,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘，众生药业报收于25.34元，较前一交易日下跌3.17%，最新总市值为215.37亿元。该股当日开盘26.0元，最高26.39元，最低25.17元，成交额达6.44亿元，换手率为3.32%。近日，众生药业披露《2026年半年度报告》。报告显示，本报告期营业收入为1,000,420,115.22元，较上年同期下降23.03%；归属于上市公司股东的净利润为111,423,979.07元，同比下降40.70%；扣除非经常性损益后的净利润为120,783,851.89元，同比下降35.26%。经营活动产生的现金流量净额为541,753,332.27元，同比增长1,265.85%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400036671.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433454","title":"众生药业（002317）披露收购控股子公司部分股权暨关联交易公告，8月17日股价上涨2.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433454","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433454?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:07","pubTimestamp":1786975657,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，众生药业报收于28.24元，较前一交易日上涨2.88%，最新总市值为240.02亿元。近日，众生药业披露《关于收购控股子公司部分股权暨关联交易的公告》。本次交易构成关联交易，已获董事会审议通过，无需提交股东大会审议，不构成重大资产重组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700034906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484959","title":"众生药业最新公告：拟2826万美元收购控股子公司众生睿创12.06%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484959","media":"证券之星","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660484959?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:01","pubTimestamp":1786964485,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称，公司拟使用自有资金2826.21万美元向SouthernOrchard、SnowOwl、BioTrack收购其合计所持有的众生睿创12.06%股权。收购完成后，公司对众生睿创持股比例由77.12%提升至89.18%，众生睿创仍为控股子公司。本次交易构成关联交易，已获董事会审议通过。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700027747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660510745","title":"公司问答丨众生药业：RAY1225注射液已获得FDA批准在美国开展超重或肥胖患者的II期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2660510745","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660510745?lang=zh_cn&edition=full","pubTime":"2026-08-17 14:42","pubTimestamp":1786948970,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0077","BK0188","002317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660012351","title":"众生药业：RAY1225注射液获FDA批准在美国开展II期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2660012351","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660012351?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:36","pubTimestamp":1786937768,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业(002317)08月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问1225是否已经启动美国的二期临床，目前进展如何？谢谢众生药业回复：您好！公司的RAY1225注射液已获得FDA批准在美国开展超重或肥胖患者的II期临床研究。公司积极寻求国际合作，组织开展国际多中心临床研究，争取早日完成相关研究，申报药物上市，为广大患者提供更多治疗选择。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700010530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928252","title":"众生药业：RAY1225注射液III期临床试验已完成全部参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928252","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658928252?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:37","pubTimestamp":1786505826,"startTime":"0","endTime":"0","summary":"RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性的III期临床试验，RAY1225注射液单药治疗2型糖尿病患者的安全性和有效性、安慰剂对照的III期临床试验和RAY1225注射液与口服降糖药物联合治疗2型糖尿病患者的安全性和有效性、司美格鲁肽注射液对照的III期临床试验均已顺利完成全部参与者入组工作，目前正在积极推进III期临床试验。基于“安全至上、循序渐进”的原则，RAY1225注射液III期临床试验沿用低剂量起始缓和爬坡的试验方案设计。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200016270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692844","title":"众生药业：乐睿灵®已形成医疗机构终端+线上平台的核心销售渠道体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692844","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658692844?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:37","pubTimestamp":1786505822,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业08月12日在投资者关系平台上答复投资者关心的问题。乐睿灵已形成医疗机构终端+线上平台的核心销售渠道体系。此外，乐睿灵已获得常规批准，公司目前正稳步推进乐睿灵向基层医疗机构、零售药店的拓展落地，逐步完善从等级医院到基层医疗机构、零售药店的全域渠道布局，全方位提升药品可及性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200016265.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658952961","title":"众生药业：中国民营药企穿越周期最朴素的样子","url":"https://stock-news.laohu8.com/highlight/detail?id=2658952961","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658952961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:44","pubTimestamp":1786423460,"startTime":"0","endTime":"0","summary":"众生药业是个例外。拆开这套操作，能看见一家中国药企穿越周期的方法论。众生药业从2010年就开启了创新转型之路，目标是让一家传统中药企业长出创新药的筋骨。众生药业决定锚定PB2靶点全力攻坚。2018年10月，众生药业设立控股子公司众生睿创，聚焦创新药物研发与商业化。复方血栓通胶囊在国内眼科内服中成药市场市占率长期稳居第一。众生药业的应对方式没有太多花活。05 成果兑现三重考验之后，众生药业交出的答卷在数据上有了回响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786331694308753150","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0077","002317","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656486693","title":"股市必读：众生药业新发布《关于全资子公司获得布瑞哌唑化学原料药上市申请批准通知书的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656486693","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656486693?lang=zh_cn&edition=full","pubTime":"2026-08-03 01:00","pubTimestamp":1785690046,"startTime":"0","endTime":"0","summary":"公司公告汇总：全资子公司获布瑞哌唑化学原料药上市申请批准通知书，登记号Y20250000228，审批结论为符合药品注册有关要求，批准注册。布瑞哌唑制剂用于治疗成人精神分裂症，2025年及2026年一季度销售额分别为878万元、1,001万元。该事项丰富公司特色原料药产品管线，有利于拓展研发及销售，但不会对公司当期经营业绩产生重大影响。药品销售受政策、市场环境等因素影响，存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300000388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655354395","title":"众生药业(002317.SZ)：原料药布瑞哌唑获得化学原料药上市申请批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2655354395","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655354395?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:28","pubTimestamp":1785490080,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，公司全资子公司广东先强药业有限公司于近日收到国家药品监督管理局核准签发的原料药布瑞哌唑《化学原料药上市申请批准通知书》。布瑞哌唑制剂用于治疗成人精神分裂症。本次原料药布瑞哌唑获得《化学原料药上市申请批准通知书》，表明该原料药已符合国家相关药品审评技术标准，已批准可在国内制剂中使用和销售，将丰富公司特色原料药产品管线，有利于公司拓展该品种的研发及销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474665.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BK0188","002317","IPOS","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655255448","title":"公司问答丨众生药业：已递交昂拉地韦片青少年单纯性甲型流感适应症的补充申请 目前正在审评审批进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2655255448","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655255448?lang=zh_cn&edition=full","pubTime":"2026-07-30 14:55","pubTimestamp":1785394545,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["002317","BK0239","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654889288","title":"众生药业（002317）披露使用闲置自有资金进行委托理财的进展公告，7月28日股价下跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654889288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654889288?lang=zh_cn&edition=full","pubTime":"2026-07-28 22:13","pubTimestamp":1785247995,"startTime":"0","endTime":"0","summary":"截至2026年7月28日收盘，众生药业报收于26.49元，较前一交易日下跌5.26%，最新总市值为225.15亿元。近日，众生药业发布《关于使用闲置自有资金进行委托理财的进展公告》。公告显示，公司于2026年7月27日和28日，通过控股子公司众生睿创分别使用3,500万元和3,000万元闲置自有资金购买东莞银行和中信银行的保本浮动收益型结构性存款产品，产品期限分别为92天和79天，起息日均为2026年7月29日，预期年化收益率分别为1.10%至1.75%和1.00%至1.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072800039681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788488478810,"stockEarnings":[{"period":"1week","weight":-0.0464},{"period":"1month","weight":-0.0815},{"period":"3month","weight":0.1381},{"period":"6month","weight":0.3942},{"period":"1year","weight":0.2206},{"period":"ytd","weight":0.323}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"69037人(较上一季度减少37.81%)","perCapita":"11124股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是中成药、化学药、原料药及中间体、中药材及中药饮片。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}